Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

03. September 2019 08:00 ET | Quelle: Atossa Genetics Inc.

Atossa Genetics Announces Completion of Enrollment and Dosing in Phase 1 Clinical Trial of New Proprietary Modified-Release Oral Endoxifen Tablet

SEATTLE, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...
13. August 2019 13:26 ET | Quelle: Atossa Genetics Inc.

Atossa Genetics Announces Second Quarter 2019 Financial Results and Provides Company Update

SEATTLE, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer...
30. Juli 2019 08:30 ET | Quelle: Atossa Genetics Inc.

Atossa Genetics CEO Steven Quay Gives Tedx Talk At University of Washington Regarding the the Relationship of Dense Breast Tissue and Breast Cancer Risk

SEATTLE, July 30, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...
17. Juli 2019 08:30 ET | Quelle: Atossa Genetics Inc.

Atossa Genetics Provides Information on FDA Expanded Access Policy and Requests

SEATTLE, July 17, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...
11. Juli 2019 08:30 ET | Quelle: Atossa Genetics Inc.

Atossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet; Phase 1 Clinical Trial Initiated

SEATTLE, July 11, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...
27. Juni 2019 08:00 ET | Quelle: Atossa Genetics Inc.

Atossa Genetics’ Preliminary Phase 2 Study Achieves Primary Endpoint: Topical Endoxifen Rapidly Reduces Breast Density

SEATTLE, June 27, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...
30. Mai 2019 08:00 ET | Quelle: Atossa Genetics Inc.

Atossa Genetics to Present at the 9th Annual LD Micro Invitational on June 4, 2019

SEATTLE, May 30, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...
13. Mai 2019 17:21 ET | Quelle: Atossa Genetics Inc.

Atossa Genetics Announces First Quarter 2019 Financial Results and Provides Company Update

SEATTLE, May 13, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and...
25. April 2019 12:00 ET | Quelle: Atossa Genetics Inc.

Atossa Genetics Provides Clinical Update at the 4th Annual Precision: Breast Cancer World R&D Summit

SEATTLE, April 25, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...
22. April 2019 08:30 ET | Quelle: Atossa Genetics Inc.

Atossa Genetics to Present at the 4th Annual Precision: Breast Cancer World R&D Summit April 25, 2019

SEATTLE, April 22, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...

Vorherige Seite